Invigor Medical Review: It Names Five Pharmacies and Not One Molecule

And then the product pages

Open /plans/glp-1-treatments/. The heading is "GLP-1 Treatments." The subheading is "Reset Balance. Rebuild Confidence." The price is $225 a month, "[i]ncludes doctor consult and supplies."

The word semaglutide does not appear on it.

That is not an impression. The page was loaded in a real browser, every accordion and toggle was force-expanded, and the visible text was searched: zero occurrences. The served HTML contains the word three times, and all three sit inside a deferred script blob in the page head — invisible to a reader and to anyone reading the page's meta tags. "GLP-1" appears nineteen times. ¹

The sibling product does the same thing. "GLP-1 + GIP Treatment," $350 a month, and tirzepatide appears zero times.

There is exactly one way to work out what you are buying, and Invigor supplies it in the disclaimer at the very bottom: "FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™… Try Invigor does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible."

So the identification is by elimination, from a list of the things it is not. That disclaimer is otherwise excellent — it continues "[c]ompounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality," which is correct and complete — and it is the single most informative sentence on the page.

Naming a molecule and naming a brand are different acts with different legal weight, which is presumably the reason for the omission. The consequence for a reader is the same either way: you cannot look up the evidence for a drug whose name you have not been told. If you want the evidence for the molecule itself, it is real and it is strong — 1,961 participants over 68 weeks for semaglutide, 2,539 over 72 weeks for tirzepatide ^{2 4} — and you can start from semaglutide or tirzepatide rather than from a page that will not say the word.

PT-141, and the approval nobody mentions

The PT-141 page is the most interesting document on the site, because it contains both the best and the worst evidence writing here, four lines apart.

The good half, verbatim: "Two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials evaluated the safety and efficacy of PT-141 in treating hypoactive sexual desire disorder in premenopausal women."

Every word of that is true. NCT02333071 and NCT02338960, both sponsored by Palatin Technologies, both phase 3, both completed, 723 and 714 participants — the RECONNECT programme, published in Obstetrics & Gynecology in 2019. ^{5 6 7} Naming the design, the phase and the population that precisely is better than almost anything else on any site reviewed here.

The bad half, immediately below: "In a double-blinded placebo-controlled study, approximately 80 percent of men developed an erection satisfactory for intercourse after using PT-141, and 68 percent of men reported an increase in sexual desire. In another study, PT-141 administration led to a dose-dependent increase in erectile activity."

Two exact percentages, two unnamed studies, and a registry that does not contain them. On August 9, 2026 a ClinicalTrials.gov free-text search for "PT-141" returned four studies, all of them in women: the two RECONNECT trials and two phase 2 studies in female sexual arousal disorder and hypoactive sexual desire disorder. A search pairing bremelanotide with erectile returned one record, and it is a phase 2 obesity study co-administering tirzepatide. ⁸

And then the omission that ties this section to the last one. Bremelanotide is an FDA-approved drug. It is marketed as Vyleesi. The word "bremelanotide" appears zero times on the page, and "Vyleesi" appears zero times. A reader is therefore never told that an approved version of this molecule exists, that they could ask a physician about it, or that its approval covers premenopausal women with acquired, generalised hypoactive sexual desire disorder — not men, and not erectile function.

The page sells a research code number for a drug that has a name.

Sermorelin: the hedge that names its own gap

Invigor's sermorelin page, $220 a month, headed "Support Youthful Energy and Sleep," makes four benefit claims. Read the qualifiers:

"Clinical studies on similar secretagogues have shown increases in muscle mass and metabolism over time."

"Growth hormone secretagogues like sermorelin have been shown to increase bone mineral content in both animal and human studies."

"Research shows that GH secretagogues similar to sermorelin can improve sleep architecture—specifically increasing time in restorative Stage 2 sleep."

Three separate concessions, in Invigor's own copy, that the evidence being invoked is for other molecules. That is genuinely more candid than the flat assertions most competitors use — and it is also a precise description of the problem.

The registry is unambiguous about how far that gap goes. On August 9, 2026, a ClinicalTrials.gov query for AREA[InterventionName]sermorelin returned 11 studies, and not one names sermorelin as its intervention. Every record is generic "growth hormone releasing hormone," or tesamorelin, or a GHRH-plus-arginine diagnostic challenge. Widening to an intervention search returns 27 studies and free text returns 42, with the same answer: zero. PubMed the same day returns 19 randomised sermorelin publications, the newest from August 2005, all measuring growth hormone secretion, growth in children, or a response to a diagnostic bolus. ⁹

A hedge that identifies the gap and then steps across it is not a disclosure. It is a well-drafted admission.

The panel that says Passed four times

Every GLP-1 page carries a section headed "Invigor's Commitment to Quality Medication." It opens: "Our partner compounding pharmacies work with a registered and certified third-party lab to run quality control checks for every lot of compounded medications prescribed and delivered to our patients."

Below it, four rows laid out like a certificate of analysis. Endotoxicity — Passed. pH Test — Passed. Sterility Test — Passed. Potency Test — Passed. Each with a clear, accurate explanation of what the test is for; the potency description even gets beyond-use dating right.

Each row also carries two fields. Date: 01-01-01. Lab: Bio Pharma.

01-01-01 is not a date on which a laboratory reported anything. It is the placeholder the template shipped with. There is no lot number, no laboratory address or accreditation, no USP chapter, no potency tolerance, and no certificate anyone can open.

This is the precise reason this site keeps "publishes testing" and "publishes a certificate" as two different questions. A page that describes a testing programme is making one claim. A page that shows four green "Passed" rows in a certificate layout is making a much stronger one, visually, while carrying less checkable information than a paragraph of prose would.

It is not the only unfilled field in production either. The About Us hero, directly under the heading "Your Health, Your Terms," reads: "We understand that in today's fast-paced world, you need a courier service that you can count on to deliver your packages and documents on time and with care." That is boilerplate written for a logistics company, live on the About page of a telehealth clinic, present in the served HTML rather than injected by a script. And the social-proof counters on every plan page render with their digits missing — "+ Happy Customers," "States Licensed," ".7★ Average Rating" — because the digit span comes back empty from the server. The home page hard-codes the same figures correctly: 35,000+, 50 states, 1,000+ reviews, 4.7 average.

That last one matters more than it looks, because "50 States Licensed" on the home page is the entire licensing disclosure. There is no state table, no per-product availability note and no state checker in the intake. The only copy of that claim a buyer sees on the page they are buying from has no number in it.

A clinical policy the marketing has not read

One more document deserves credit, and one more contradiction deserves naming.

The clinical policy, last updated August 14, 2025, is a real document. It states that treatment is "never cosmetic or performance enhancement," that all prescribing sits under the oversight of Dr. Hamilton, Medical Director, and that Invigor does not treat "[a]thletic performance enhancement," "[c]osmetic improvements or aesthetic goals," or "[b]ody composition preferences without clinical indication." Very few companies in this market publish a scope-of-care refusal at all.

Now read the sermorelin page's testimonials: "Workouts improved and soreness faded much faster." "Recovery time shrank and daily energy rose." Or the NAD+ page: "Focus sharpened and afternoon energy slumps vanished."

Those testimonials are also, on inspection, not what they appear to be. The ten on the sermorelin page are attributed to Kevin, Laura, Mark, Nina, Owen, Paige, Quinn, Rita, Sean and Tessa — sequential initials, K through T — under the label "Verified Customers." The NAD+ page runs a different alphabetical set. Sequential-alphabet naming is what placeholder data looks like, and it is sitting under a word that asserts the opposite.

The policy is better than the pages it governs. That is the shape of this whole review: the documents Invigor writes deliberately — the pharmacy list, the disclaimer, the clinical policy, the RECONNECT paragraph — are careful and unusually good. The pages it ships are running on a template nobody finished filling in.